FibroGen Inc (NASDAQ:FGEN) – Equities researchers at Jefferies Financial Group issued their FY2021 earnings estimates for shares of FibroGen in a research note issued on Thursday, August 8th. Jefferies Financial Group analyst M. Yee anticipates that the biopharmaceutical company will earn ($0.25) per share for the year.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $1.75. FibroGen had a net margin of 13.90% and a return on equity of 9.62%. The company had revenue of $191.57 million during the quarter, compared to analyst estimates of $29.03 million. During the same period in the previous year, the business earned ($0.28) EPS. The firm’s revenue for the quarter was up 335.9% on a year-over-year basis.

A number of other equities analysts have also weighed in on the stock. ValuEngine lowered shares of FibroGen from a “buy” rating to a “hold” rating in a report on Saturday. BidaskClub upgraded shares of FibroGen from a “buy” rating to a “strong-buy” rating in a report on Wednesday, July 31st. William Blair reaffirmed a “hold” rating on shares of FibroGen in a research report on Tuesday, July 2nd. TheStreet downgraded shares of FibroGen from a “c-” rating to a “d+” rating in a research report on Friday, May 24th. Finally, Piper Jaffray Companies reaffirmed a “positive” rating and issued a $40.00 target price (down previously from $65.00) on shares of FibroGen in a research report on Monday, May 27th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $61.00.

Shares of NASDAQ FGEN opened at $45.09 on Monday. FibroGen has a twelve month low of $33.51 and a twelve month high of $62.00. The stock has a market cap of $3.98 billion, a price-to-earnings ratio of -43.78 and a beta of 1.86. The stock has a 50 day moving average price of $45.79. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.16 and a current ratio of 6.16.

In other FibroGen news, Director Kalevi Kurkijarvi sold 6,000 shares of FibroGen stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $45.22, for a total value of $271,320.00. Following the completion of the sale, the director now owns 34,400 shares of the company’s stock, valued at approximately $1,555,568. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Thomas B. Neff sold 39,636 shares of FibroGen stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $46.74, for a total transaction of $1,852,586.64. Following the completion of the sale, the chief executive officer now directly owns 2,402,842 shares of the company’s stock, valued at approximately $112,308,835.08. The disclosure for this sale can be found here. In the last ninety days, insiders sold 248,174 shares of company stock valued at $10,466,296. 7.83% of the stock is currently owned by insiders.

Several hedge funds have recently modified their holdings of FGEN. Lindbrook Capital LLC grew its position in shares of FibroGen by 150.0% during the 1st quarter. Lindbrook Capital LLC now owns 500 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 300 shares during the period. FTB Advisors Inc. bought a new stake in shares of FibroGen during the 1st quarter valued at $27,000. Manchester Capital Management LLC bought a new stake in shares of FibroGen during the 1st quarter valued at $39,000. Cornerstone Advisors Inc. grew its position in shares of FibroGen by 672.8% during the 1st quarter. Cornerstone Advisors Inc. now owns 796 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 693 shares during the period. Finally, Quadrant Capital Group LLC bought a new stake in shares of FibroGen during the 1st quarter valued at $45,000. 64.67% of the stock is owned by hedge funds and other institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Further Reading: Gross Domestic Product (GDP)

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.